Evidence map›Paper›PMID 41086173›Full record

ArticlePloS one2025

Quantification of timelapse 3D tumor spheroid killing activity of NK cells using a live-cell imaging system.

Jakkrapatra Srisantitham, Nontaphat Thongsin, Siriwal Suwanpitak, Methichit Wattanapanitch

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jakkrapatra SrisantithamSiriraj Center for Regenerative Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Nontaphat ThongsinSiriraj Center for Regenerative Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Siriwal SuwanpitakSiriraj Center for Regenerative Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Methichit WattanapanitchSiriraj Center for Regenerative Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.ORCID https://orcid.org/0000-0003-3145-733X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells are critical components of the immune system, responsible for recognizing and eliminating a wide range of abnormal cells, including those infected by pathogens or transformed into cancerous cells. Their potent cytotoxic functions, encompassing the direct release of cytotoxic granules, antibody-dependent cell cytotoxicity (ADCC), and the expression of apoptosis-inducing ligands, make NK cells a promising therapeutic product in cancer immunotherapy. This study presents a detailed protocol for assessing NK cell-mediated cytotoxicity against three-dimensional (3D) tumor spheroids using a live-cell imaging system, offering a more physiologically relevant model compared to traditional 2D cultures. Utilizing this 3D spheroid model, we explored the dynamics of NK cell killing activity against two aggressive solid cancer cell lines, cholangiocarcinoma (KKU-213A) and triple-negative breast cancer (MDA-MB-231), across varying effector-to-target (E:T) ratios. Our findings reveal a dose-dependent increase in NK cell activity, with higher E:T ratios yielding more pronounced tumor cell death. Real-time imaging further demonstrated distinct differences in the morphology and cell death patterns of the two cell lines, with MDA-MB-231 cells exhibiting a faster response to NK cell cytotoxicity. These findings underscore the utility of 3D spheroid models and live-cell imaging for studying NK cell function and advancing the development of NK cell-based immunotherapies. The standardized protocol detailed herein provides a valuable insights into immune surveillance and therapeutic applications.

Indexed as

Killer Cells, NaturalSpheroids, CellularCell Line, TumorCytotoxicity, ImmunologicHumans

Identifiers

PMID41086173
PMCPMC12520373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.